3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Clinical Amyloid Imaging.

      1 , 2 , 3
      Seminars in nuclear medicine
      Elsevier BV

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Amyloid plaques, along with neurofibrillary tangles, are a neuropathologic hallmark of Alzheimer disease (AD). Recently, amyloid PET radiotracers have been developed and approved for clinical use in the evaluation of suspected neurodegenerative disorders. In both research and clinical settings, amyloid PET imaging has provided important diagnostic and prognostic information for the management of patients with possible AD, mild cognitive impairment (MCI), and other challenging diagnostic presentations. Although the overall impact of amyloid imaging is still being evaluated, the Society of Nuclear Medicine and Molecular Imaging and Alzheimer's Association Amyloid Imaging Task Force have created appropriate use criteria for the standard clinical use of amyloid PET imaging. By the appropriate use criteria, amyloid imaging is appropriate for patients with (1) persistent or unexplained MCI, (2) AD as a possible but still uncertain diagnosis after expert evaluation and (3) atypically early-age-onset progressive dementia. To better understand the clinical and economic effect of amyloid imaging, the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) study is an ongoing large multicenter study in the United States, which is evaluating how amyloid imaging affects diagnosis, management, and outcomes for cognitively impaired patients who cannot be completely evaluated by clinical assessment alone. Multiple other large-scale studies are evaluating the prognostic role of amyloid PET imaging for predicting MCI progression to AD in general and high-risk populations. At the same time, amyloid imaging is an important tool for evaluating potential disease-modifying therapies for AD. Overall, the increased use of amyloid PET imaging has led to a better understanding of the strengths and limitations of this imaging modality and how it may best be used with other clinical, molecular, and imaging assessment techniques for the diagnosis and management of neurodegenerative disorders.

          Related collections

          Author and article information

          Journal
          Semin Nucl Med
          Seminars in nuclear medicine
          Elsevier BV
          1558-4623
          0001-2998
          Jan 2017
          : 47
          : 1
          Affiliations
          [1 ] Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT. Electronic address: Atul.Mallik@hsc.utah.edu.
          [2 ] Department of Nuclear Medicine, University of Cologne, Cologne, Germany.
          [3 ] Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT.
          Article
          S0001-2998(16)30078-2
          10.1053/j.semnuclmed.2016.09.005
          27987555
          545740d5-0139-450b-a2c9-6b8edf3d70d7
          History

          Comments

          Comment on this article